Most Read Articles
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.
Tristan Manalac, 27 Jun 2017
Prolonged sleep duration is an independent predictor of higher incident atrial fibrillation (AF) risks in a Chinese population, reports a new prospective, population-based study.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.

Lower risk of respiratory-related hospitalization after high-dose influenza vaccination in the elderly

Roshini Claire Anthony
01 Aug 2017

Elderly individuals residing in nursing homes had a lower risk of respiratory-related hospital admissions during the influenza season after receiving a high-dose influenza vaccine compared with a standard-dose vaccine, a recent study found.

Eight hundred and twenty three nursing care facilities in the US participated in the study. Individuals aged ≥65 years (mean age 83.6 years, 72 percent female) who had been living in the nursing homes for ≥90 days were randomized to receive either high-dose (60 µg antigen per virus strain; n=26,639) or standard-dose (15 µg antigen per virus strain; n=26,369) influenza vaccine for the 2013–2014 influenza season.

Hospital admission due to respiratory issues was lower among patients who received the high-dose vaccine compared with the standard-dose vaccine (0.185 vs 0.211 per 1,000 resident-days; adjusted relative risk [adjRR], 0.873, 95 percent confidence interval [CI], 0.776–0.982; p=0.023). [Lancet Respir Med 2017;doi:10.1016/S2213-2600(17)30235-7]

Pneumonia- related hospital admissions were also reduced among individuals receiving the high-dose vaccine compared with the standard dose (0.067 vs 0.084 per 1,000 resident-days; adjRR, 0.791, 95 percent CI, 0.267–0.953; p=0.013), as were all-cause admissions (1.021 vs 1.113 per 1,000 resident-days; adjRR, 0.915, 95 percent CI, 0.863–0.970; p=0.0028), while all-cause mortality rate was not affected by vaccine dose (p=0.57).

The reduction in all-cause admission suggests that the impact of the high-dose vaccine extends beyond that of influenza-related respiratory conditions, said the researchers. 

“Establishing improved vaccine effectiveness in a nursing home population is noteworthy, considering this population typically has a reduced vaccine response because of immune senescence and multiple morbidities, and are at a high risk for being admitted to hospital for multiple reasons, in addition to respiratory illness,” said the researchers.

“[S]tandard-dose inactivated influenza vaccines ... are known to be less immunogenic in older adults than in healthier, younger adults,” commented Drs Marc-Alain Widdowson and Joseph Bresee from the US Centers for Disease Control and Prevention, in Nairobi, Kenya, and Atlanta, Georgia, US, respectively. [Lancet Respir Med 2017;doi:10.1016/S2213-2600(17)30290-4]

“[T]his study presents strong evidence that influenza has a major role in seasonal hospital admissions of older nursing home residents ... it seems that high-dose influenza vaccines can reduce this burden substantially better than a standard-dose vaccine,” they said.

However, the researchers cautioned that the main circulating virus strain during the 2013–2014 influenza season was A(H1N1)pdm09, a strain that is considered less virulent than the A/H3N2 strains, and which may have affected the findings, particularly among the elderly population.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.
Tristan Manalac, 27 Jun 2017
Prolonged sleep duration is an independent predictor of higher incident atrial fibrillation (AF) risks in a Chinese population, reports a new prospective, population-based study.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.